Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

KRAS mutation status is associated with enhanced dependency on folate metabolism pathways in non-small cell lung cancer cells.

Moran DM, Trusk PB, Pry K, Paz K, Sidransky D, Bacus SS.

Mol Cancer Ther. 2014 Jun;13(6):1611-24. doi: 10.1158/1535-7163.MCT-13-0649. Epub 2014 Mar 31.

2.

A recombinant decoy comprising EGFR and ErbB-4 inhibits tumor growth and metastasis.

Lindzen M, Carvalho S, Starr A, Ben-Chetrit N, Pradeep CR, Köstler WJ, Rabinkov A, Lavi S, Bacus SS, Yarden Y.

Oncogene. 2012 Jul 26;31(30):3505-15. doi: 10.1038/onc.2011.518. Epub 2011 Nov 21.

3.

Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitors.

Xia W, Liu Z, Zong R, Liu L, Zhao S, Bacus SS, Mao Y, He J, Wulfkuhle JD, Petricoin EF 3rd, Osada T, Yang XY, Hartman ZC, Clay TM, Blackwell KL, Lyerly HK, Spector NL.

Mol Cancer Ther. 2011 Aug;10(8):1367-74. doi: 10.1158/1535-7163.MCT-10-0991. Epub 2011 Jun 14.

4.

Activation of AMPK is necessary for killing cancer cells and sparing cardiac cells.

Shell SA, Lyass L, Trusk PB, Pry KJ, Wappel RL, Bacus SS.

Cell Cycle. 2008 Jun 15;7(12):1769-75. Epub 2008 Jun 30.

PMID:
18594201
5.

A reciprocal tensin-3-cten switch mediates EGF-driven mammary cell migration.

Katz M, Amit I, Citri A, Shay T, Carvalho S, Lavi S, Milanezi F, Lyass L, Amariglio N, Jacob-Hirsch J, Ben-Chetrit N, Tarcic G, Lindzen M, Avraham R, Liao YC, Trusk P, Lyass A, Rechavi G, Spector NL, Lo SH, Schmitt F, Bacus SS, Yarden Y.

Nat Cell Biol. 2007 Aug;9(8):961-9. Epub 2007 Jul 22.

PMID:
17643115
6.

Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells.

Spector NL, Yarden Y, Smith B, Lyass L, Trusk P, Pry K, Hill JE, Xia W, Seger R, Bacus SS.

Proc Natl Acad Sci U S A. 2007 Jun 19;104(25):10607-12. Epub 2007 Jun 7.

7.
8.

Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy.

Friedman LM, Rinon A, Schechter B, Lyass L, Lavi S, Bacus SS, Sela M, Yarden Y.

Proc Natl Acad Sci U S A. 2005 Feb 8;102(6):1915-20. Epub 2005 Jan 31.

9.

Epigen, the last ligand of ErbB receptors, reveals intricate relationships between affinity and mitogenicity.

Kochupurakkal BS, Harari D, Di-Segni A, Maik-Rachline G, Lyass L, Gur G, Kerber G, Citri A, Lavi S, Eilam R, Chalifa-Caspi V, Eshhar Z, Pikarsky E, Pinkas-Kramarski R, Bacus SS, Yarden Y.

J Biol Chem. 2005 Mar 4;280(9):8503-12. Epub 2004 Dec 17.

10.
11.

Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma.

Esteva FJ, Sahin AA, Smith TL, Yang Y, Pusztai L, Nahta R, Buchholz TA, Buzdar AU, Hortobagyi GN, Bacus SS.

Cancer. 2004 Feb 1;100(3):499-506.

12.

Cyclin E and survival in patients with breast cancer.

Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, Bedrosian I, Knickerbocker C, Toyofuku W, Lowe M, Herliczek TW, Bacus SS.

N Engl J Med. 2002 Nov 14;347(20):1566-75. Erratum in: N Engl J Med 2003 Jan 9;348(2):186.

13.

AKT2 is frequently upregulated in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival.

Bacus SS, Altomare DA, Lyass L, Chin DM, Farrell MP, Gurova K, Gudkov A, Testa JR.

Oncogene. 2002 May 16;21(22):3532-40.

14.

Expression of erbB/HER receptors, heregulin and P38 in primary breast cancer using quantitative immunohistochemistry.

Esteva FJ, Hortobagyi GN, Sahin AA, Smith TL, Chin DM, Liang SY, Pusztai L, Buzdar AU, Bacus SS.

Pathol Oncol Res. 2001;7(3):171-7.

15.

Absence of type I estrogen receptors in choroidal melanoma: analysis of Collaborative Ocular Melanoma Study (COMS) eyes.

Grostern RJ, Slusker Shternfeld I, Bacus SS, Gilchrist K, Zimbric ML, Albert DM; Collaborative Ocular Melanoma Study Group.

Am J Ophthalmol. 2001 Jun;131(6):788-91.

PMID:
11384577
16.

Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53.

Bacus SS, Gudkov AV, Lowe M, Lyass L, Yung Y, Komarov AP, Keyomarsi K, Yarden Y, Seger R.

Oncogene. 2001 Jan 11;20(2):147-55.

17.

ErbB tyrosine kinases and the two neuregulin families constitute a ligand-receptor network.

Pinkas-Kramarski R, Shelly M, Guarino BC, Wang LM, Lyass L, Alroy I, Alimandi M, Kuo A, Moyer JD, Lavi S, Eisenstein M, Ratzkin BJ, Seger R, Bacus SS, Pierce JH, Andrews GC, Yarden Y.

Mol Cell Biol. 1998 Oct;18(10):6090-101. Erratum in: Mol Cell Biol 1998 Dec;18(12):7602. Alamandi M [corrected to Alimandi M].

18.

Epiregulin is a potent pan-ErbB ligand that preferentially activates heterodimeric receptor complexes.

Shelly M, Pinkas-Kramarski R, Guarino BC, Waterman H, Wang LM, Lyass L, Alimandi M, Kuo A, Bacus SS, Pierce JH, Andrews GC, Yarden Y.

J Biol Chem. 1998 Apr 24;273(17):10496-505.

19.

The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin.

Pinkas-Kramarski R, Lenferink AE, Bacus SS, Lyass L, van de Poll ML, Klapper LN, Tzahar E, Sela M, van Zoelen EJ, Yarden Y.

Oncogene. 1998 Mar 12;16(10):1249-58.

20.
21.

Intracellular localization of p53 tumor suppressor protein in gamma-irradiated cells is cell cycle regulated and determined by the nucleus.

Komarova EA, Zelnick CR, Chin D, Zeremski M, Gleiberman AS, Bacus SS, Gudkov AV.

Cancer Res. 1997 Dec 1;57(23):5217-20.

22.

Transgenic mice with p53-responsive lacZ: p53 activity varies dramatically during normal development and determines radiation and drug sensitivity in vivo.

Komarova EA, Chernov MV, Franks R, Wang K, Armin G, Zelnick CR, Chin DM, Bacus SS, Stark GR, Gudkov AV.

EMBO J. 1997 Mar 17;16(6):1391-400.

23.

Neu differentiation factor (Heregulin) activates a p53-dependent pathway in cancer cells.

Bacus SS, Yarden Y, Oren M, Chin DM, Lyass L, Zelnick CR, Kazarov A, Toyofuku W, Gray-Bablin J, Beerli RR, Hynes NE, Nikiforov M, Haffner R, Gudkov A, Keyomarsi K.

Oncogene. 1996 Jun 20;12(12):2535-47.

PMID:
8700512
24.

An immunological approach reveals biological differences between the two NDF/heregulin receptors, ErbB-3 and ErbB-4.

Chen X, Levkowitz G, Tzahar E, Karunagaran D, Lavi S, Ben-Baruch N, Leitner O, Ratzkin BJ, Bacus SS, Yarden Y.

J Biol Chem. 1996 Mar 29;271(13):7620-9.

25.
26.
27.

HER4 expression correlates with cytotoxicity directed by a heregulin-toxin fusion protein.

Siegall CB, Bacus SS, Cohen BD, Plowman GD, Mixan B, Chace D, Chin DM, Goetze A, Green JM, Hellström I, et al.

J Biol Chem. 1995 Mar 31;270(13):7625-30.

28.

Medullary carcinoma is associated with expression of intercellular adhesion molecule-1. Implication to its morphology and its clinical behavior.

Bacus SS, Zelnick CR, Chin DM, Yarden Y, Kaminsky DB, Bennington J, Wen D, Marcus JN, Page DL.

Am J Pathol. 1994 Dec;145(6):1337-48.

29.
30.

Expression of the erbB-2 family of growth factor receptors and their ligands in breast cancers. Implication for tumor biology and clinical behavior.

Bacus SS, Zelnick CR, Plowman G, Yarden Y.

Am J Clin Pathol. 1994 Oct;102(4 Suppl 1):S13-24. Review.

PMID:
7942609
31.

Neu differentiation factor (heregulin) induces expression of intercellular adhesion molecule 1: implications for mammary tumors.

Bacus SS, Gudkov AV, Zelnick CR, Chin D, Stern R, Stancovski I, Peles E, Ben-Baruch N, Farbstein H, Lupu R, et al.

Cancer Res. 1993 Nov 1;53(21):5251-61.

32.

Application of image analysis to the evaluation of cellular prognostic factors in breast carcinoma.

Bacus SS, Ruby SG.

Pathol Annu. 1993;28 Pt 1:179-204. Review. No abstract available.

PMID:
8093211
33.

HER-2/neu oncogene expression, DNA ploidy and proliferation index in breast cancer.

Bacus SS, Chin DM, Stern RK, Ortiz R, Ruby SG, Weinberg DS.

Anal Quant Cytol Histol. 1992 Dec;14(6):433-45.

PMID:
1363346
34.

A ligand for the erbB-2 oncogene product (gp30) induces differentiation of human breast cancer cells.

Bacus SS, Huberman E, Chin D, Kiguchi K, Simpson S, Lippman M, Lupu R.

Cell Growth Differ. 1992 Jul;3(7):401-11.

35.

Tumor-inhibitory monoclonal antibodies to the HER-2/Neu receptor induce differentiation of human breast cancer cells.

Bacus SS, Stancovski I, Huberman E, Chin D, Hurwitz E, Mills GB, Ullrich A, Sela M, Yarden Y.

Cancer Res. 1992 May 1;52(9):2580-9.

36.

Neu differentiation factor: a transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unit.

Wen D, Peles E, Cupples R, Suggs SV, Bacus SS, Luo Y, Trail G, Hu S, Silbiger SM, Levy RB, et al.

Cell. 1992 May 1;69(3):559-72.

PMID:
1349853
37.

Isolation of the neu/HER-2 stimulatory ligand: a 44 kd glycoprotein that induces differentiation of mammary tumor cells.

Peles E, Bacus SS, Koski RA, Lu HS, Wen D, Ogden SG, Levy RB, Yarden Y.

Cell. 1992 Apr 3;69(1):205-16.

PMID:
1348215
39.

Ploidy analysis of epithelial ovarian cancers using image cytometry.

Berchuck A, Boente MP, Kerns BJ, Kinney RB, Soper JT, Clarke-Pearson DL, Bast RC Jr, Bacus SS.

Gynecol Oncol. 1992 Jan;44(1):61-5.

PMID:
1370427
40.
41.
42.

HER-2/neu oncogene expression and proliferation in breast cancers.

Bacus SS, Ruby SG, Weinberg DS, Chin D, Ortiz R, Bacus JW.

Am J Pathol. 1990 Jul;137(1):103-11.

43.

HER-2/neu oncogene expression and DNA ploidy analysis in breast cancer.

Bacus SS, Bacus JW, Slamon DJ, Press MF.

Arch Pathol Lab Med. 1990 Feb;114(2):164-9.

PMID:
1967930
44.
45.

Comparison of the Papanicolaou and Feulgen staining methods for DNA quantification by image analysis.

Gurley AM, Hidvegi DF, Bacus JW, Bacus SS.

Cytometry. 1990;11(4):468-74.

46.

Biological grading of breast cancer using antibodies to proliferating cells and other markers.

Bacus SS, Goldschmidt R, Chin D, Moran G, Weinberg D, Bacus JW.

Am J Pathol. 1989 Nov;135(5):783-92.

Supplemental Content

Loading ...
Support Center